1
|
Hanif AM, Rehman A, Bushra R, Aslam N, Alam S, Dawaba HM, Dawaba AM, Sayed OM. Dexibuprofen enteric film-coated tablets: design, characterization and pharmacokinetic analysis in human volunteers. Pharm Dev Technol 2024:1-9. [PMID: 39231255 DOI: 10.1080/10837450.2024.2398537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2024] [Revised: 08/22/2024] [Accepted: 08/27/2024] [Indexed: 09/06/2024]
Abstract
OBJECTIVE This study aimed to develop a stable and scalable enteric film-coated tablet for the gastric irritant dexibuprofen. METHODS Utilizing direct compression with super-disintegration (crospovidone), the optimal core batches were coated with Opadry white seal coat and enterically coated with Eudragit®L100 with pigment (Talc), demonstrating a 12% weight increase; release and integrity were assessed using specific pH buffers and SEM, with stability testing confirming a six-month shelf life at 40 °C and 75% RH. RESULTS The optimized formulation achieved 99.87% release in phosphate buffer within 60 min, maintained integrity for 120 min in acidic conditions, and exhibited superior bioavailability compared to Innovifen with relative bioavailability ≈of 121% and elevated Cmax (18.35 µg/ml compared to 11.1 µg/ml). CONCLUSION These results highlight the potential of this formulation to enhance patient safety and efficacy through delayed enteric technology and fast intestinal release.
Collapse
Affiliation(s)
- Anas M Hanif
- Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi, Pakistan
| | - Abdul Rehman
- Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi, Pakistan
| | - Rabia Bushra
- Department of Pharmaceutics, Faculty of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan
| | - Nousheen Aslam
- Mohammad Al-Mana College for Medical Sciences, Dammam, Saudi Arabia
| | - Shazia Alam
- Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan
| | - Hamdy M Dawaba
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo, Egypt
- Department of Pharmaceutics, Faculty of Pharmacy, Sinai University-Kantara Branch, Ismailia, Egypt
| | - Aya M Dawaba
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City, Cairo, Egypt
| | - Ossama M Sayed
- Department of Pharmaceutics, Faculty of Pharmacy, Sinai University-Kantara Branch, Ismailia, Egypt
| |
Collapse
|
2
|
Nemati S, Mottaghi M, Karami P, Mirjalali H. Development of solid lipid nanoparticles-loaded drugs in parasitic diseases. DISCOVER NANO 2024; 19:7. [PMID: 38175309 PMCID: PMC10767167 DOI: 10.1186/s11671-023-03955-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Accepted: 12/29/2023] [Indexed: 01/05/2024]
Abstract
Parasites cause illnesses with broad spectrum of symptoms from mild to severe, and are responsible for a significant number of outbreaks in the world. Current anti-parasitic drugs are toxic and have significant side effects. Nano-carriers are believed to obviate the limitations of conventional drugs via decreasing side effects and increasing target delivery and drug permeability with a controlled prolonged release of a drug. Solid lipid nanoparticles (SLNs) are lipid nanoparticles (LNPs), which have frequently been practiced. Suitable release rate, stability, and target delivery make SLNs a good alternative for colloidal carriers. SLNs are supposed to have great potential to deliver natural products with anti-parasitic properties. Nanoparticles have employed to improve stability and capacity loading of SLNs, during recent years. This review describes development of SLNs, the methods of preparation, characterization, and loaded drugs into SLNs in parasitic diseases. In addition, we summarize recent development in anti-parasitic SLNs-loaded drugs.
Collapse
Affiliation(s)
- Sara Nemati
- Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mahsa Mottaghi
- Department of Biology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Parisa Karami
- Department of Biology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Hamed Mirjalali
- Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
3
|
Coussot G, Le Postollec A, Delbecq S, Dobrijevic M. Freeze-drying of few microliters of antibody formulations to implement 384-wells homogeneous instant assays. Anal Chim Acta 2023; 1277:341660. [PMID: 37604613 DOI: 10.1016/j.aca.2023.341660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 07/03/2023] [Accepted: 07/25/2023] [Indexed: 08/23/2023]
Abstract
Enzyme-linked immunosorbent assay protocols have traditionally complex workflows with several intensive wash steps. Analytical tools with both shorter time-to-result and hands-on-time using smaller sample and assays reagents volumes are now investigated. In this context, fluorescence resonance energy transfer (FRET)-based assays are emerging as one of the most promising analytical tools in high-throughput screening (HTS). These immunoassays allow fast quantification of antigens at the nano-gram level in a final assay volume of only a few μL. We used a homogeneous time-resolved FRET (called HTRF) assay to develop a freeze-dried screening and ready-to-use format with only one rehydration step called "instant assay". To assure optimal performance of the developed homogeneous instant assay, we investigated the critical quality attributes by studying the functionality and stability of the critical reagents and fluorophores. The cyclic adenosine 3'-5'-monophosphate (cAMP) was selected as the antigen target. We tested various formulations (with different buffers, sugars, bulking reagents, surfactants and co-solvants) combined with a slow freezing and the use of an aluminium plate holder during the freeze-drying of few microliter of bioreagents. The optimized freeze-drying procedure permits to preserve more than 70% of Ab recognition properties. The developed off-the-shelf homogeneous FRET immunoassay allows direct and fast quantification of cAMP at a nanogram level.
Collapse
Affiliation(s)
- G Coussot
- Faculté des Sciences Pharmaceutiques et Biologiques, Université de Montpellier, 15 Avenue Charles Flahault, 34090, Montpellier, France.
| | - A Le Postollec
- Laboratoire d'astrophysique de Bordeaux (LAB), CNRS UMR 5804, Université de Bordeaux, B18N, allée Geoffroy Saint-Hilaire, 33615, Pessac, France
| | - S Delbecq
- Centre de Biologie Structurale (CBS), INSERM U1054, CNRS UMR 5048, Université de Montpellier, 34090, Montpellier, France
| | - M Dobrijevic
- Laboratoire d'astrophysique de Bordeaux (LAB), CNRS UMR 5804, Université de Bordeaux, B18N, allée Geoffroy Saint-Hilaire, 33615, Pessac, France
| |
Collapse
|
4
|
Khan A, Ahmad L, Raza F, Khan SA, Ali T. Editorial: The practical implication of clinical pharmacokinetics in drug development, pharmaceutical analysis, and clinical research. Front Pharmacol 2023; 14:1252030. [PMID: 37587983 PMCID: PMC10426746 DOI: 10.3389/fphar.2023.1252030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Accepted: 07/17/2023] [Indexed: 08/18/2023] Open
Affiliation(s)
- Abad Khan
- Department of Pharmacy, University of Swabi, Swabi, Pakistan
| | - Lateef Ahmad
- Department of Pharmacy, University of Swabi, Swabi, Pakistan
| | - Faisal Raza
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China
| | - Saeed Ahmad Khan
- Department of Pharmacy, Kohat University of Science and Technology, Kohat, Pakistan
| | - Tahir Ali
- Department of Comparative Biology and Experimental Medicine, University of Calgary (UofC), Calgary, NW, Canada
| |
Collapse
|
5
|
Zhang J, Lu J, Zhang Y, Wang Y. A LC-MS/MS method for determination of clenbuterol enantiomers in animal tissues and its application to the enantioselective distribution in Bama mini-pigs. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1226:123790. [PMID: 37329777 DOI: 10.1016/j.jchromb.2023.123790] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 06/05/2023] [Accepted: 06/08/2023] [Indexed: 06/19/2023]
Abstract
OBJECTIVES To establish and validate a simple and reliable analytical method for separation and determination of clenbuterol enantiomers (R-(-)-clenbuterol & S-(+)-clenbuterol) in animal tissues, and apply it to the enantioselective distribution of clenbuterol in Bama mini-pigs. METHODS A LC-MS/MS analytical method was developed and validated in positive multiple reaction monitoring mode with electrospray ionization. After perchloric acid deproteinization, samples were pretreated only by one step liquid-liquid extraction using tert-butyl methyl ether under strong alkaline condition. Teicoplanin was used as chiral selector and 10 mM ammonium formate methanol solution was used as mobile phase. The optimized chromatographic separation conditions were completed in 8 min. Two chiral isomers in 11 edible tissues from Bama mini-pigs were investigated. RESULTS R-(-)-clenbuterol and S-(+)-clenbuterol can be baseline separated and accurately analyzed with a linear range of 5-500 ng/g. Accuracies ranged from -11.9-13.0% for R-(-)-clenbuterol and -10.2-13.2% for S-(+)-clenbuterol, intra-day and inter-day precisions were between 0.7 and 6.1% for R-(-)-clenbuterol and 1.6-5.9% for S-(+)-clenbuterol. R/S ratios in edible tissues of pigs were all significantly lower than 1. CONCLUSIONS The analytical method has good specificity and robustness in determination of R-(-)-clenbuterol and S-(+)-clenbuterol in animal tissues, and can be used as a routine analysis method for food safety and doping control. There is a significant difference in R/S ratio between pig feeding tissues and pharmaceutical preparations (racemate with R/S ratio of 1), which makes it possible to identify the source of clenbuterol in doping control and investigation.
Collapse
Affiliation(s)
- Jianli Zhang
- China Institute of Sport Science, No.11 Stadium Road, Dongcheng District, Beijing 100061, China.
| | - Jianghai Lu
- China Anti-Doping Agency, 1st Anding Road, Chaoyang District, Beijing 100029, China
| | - Yinong Zhang
- China Anti-Doping Agency, 1st Anding Road, Chaoyang District, Beijing 100029, China
| | - Yan Wang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 1st Xiannongtan Street, Xicheng District, Beijing 100050, China
| |
Collapse
|
6
|
Gong X, Liu W, Cao Y, Wang R, Liang N, Cao L, Li J, Tu P, Song Y. Integrated strategy for widely targeted metabolome characterization of Peucedani Radix. J Chromatogr A 2022; 1678:463360. [PMID: 35908514 DOI: 10.1016/j.chroma.2022.463360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 07/18/2022] [Accepted: 07/20/2022] [Indexed: 11/26/2022]
Abstract
Herbal medicines (HMs) are widely recognized as extremely complicated matrices, resulting in a great challenge for the existing analytical approaches to characterize the widely targeted metabolome. The primary obstacles include high-level structural diversity, broad concentration range, large polarity span, insufficient authentic compounds and frequent occurrences of isomers, even enantiomers. Here, we aimed to propose an integrated strategy being able to circumvent the technical barriers, and a well-known HM namely Peucedani Radix was employed to illustrate and justify the applicability. Regarding qualitative analysis, the hydrophilic metabolites were detected with HILIC-predictive multiple-reaction monitoring mode, and structurally identified by matching predefined identities with authentic compounds or information archived in relevant databases. After RPLC-MS/MS measurement, full collision energy ramp-MS2 spectrum in combination with quantum structural calculation was applied to confirmatively identify those less polar components, mainly angular-type pyranocoumarins (APs). For quantitative analysis, achiral-chiral RPLC/HILIC was configured for chromatographic separations because the analytes spanned a large polarity range and involved many enantiomers. A quasi-content concept was employed for comprehensively relative quantitation through constructing a so-called universal metabolome standard (UMS) sample and building calibration curves by assaying serial diluted UMS solutions. Consequently, high-confidence structural annotation and relatively quantitative analysis were achieved for 103 compounds, in total. After multivariate statistical analysis, some APs, e.g., (3'S)-praeruptorin A, (3'S)-praeruptorin B, (3'S)-praeruptorin E, as well as several primary metabolites were screened out as the prominent contributors for inter-batch variations. Together, current study shows a promising strategy enabling widely targeted metabolomics of, but not limited to, HMs.
Collapse
Affiliation(s)
- Xingcheng Gong
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Wenjing Liu
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Yan Cao
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Rongye Wang
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Naiyun Liang
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Libo Cao
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Jun Li
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Pengfei Tu
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China
| | - Yuelin Song
- Modern Research Center for Traditional Chinese Medicine, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
| |
Collapse
|
7
|
A novel oral medicated jelly for enhancement of etilefrine hydrochloride bioavailability: In vitro characterization and pharmacokinetic evaluation in healthy human volunteers. Saudi Pharm J 2022; 30:1435-1447. [DOI: 10.1016/j.jsps.2022.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Accepted: 07/19/2022] [Indexed: 11/21/2022] Open
|
8
|
Elshafeey AH, El-Dahmy RM. Formulation and Development of Oral Fast-Dissolving Films Loaded with Nanosuspension to Augment Paroxetine Bioavailability: In Vitro Characterization, Ex Vivo Permeation, and Pharmacokinetic Evaluation in Healthy Human Volunteers. Pharmaceutics 2021; 13:pharmaceutics13111869. [PMID: 34834284 PMCID: PMC8620498 DOI: 10.3390/pharmaceutics13111869] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Revised: 10/26/2021] [Accepted: 11/01/2021] [Indexed: 01/10/2023] Open
Abstract
Paroxetine (PX) is the most potent serotonin reuptake inhibitor utilized in depression and anxiety treatment. It has drawbacks, such as having a very bitter taste, low water solubility, and undergoing extensive first pass metabolism, leading to poor oral bioavailability (<50%). This work aimed to develop and optimize palatable oral fast-dissolving films (OFDFs) loaded with a paroxetine nanosuspension. A PX nanosuspension was prepared to increase the PX solubility and permeability via the buccal mucosa. The OFDFs could increase PX bioavailability due to their rapid dissolution in saliva, without needing water, and the rapid absorption of the loaded drug through the buccal mucosa, thus decreasing the PX metabolism in the liver. OFDFs also offer better convenience to patients with mental illness, as well as pediatric, elderly, and developmentally disabled patients. The PX nanosuspension was characterized by particle size, poly dispersity index, and zeta potential. Twelve OFDFs were formulated using a solvent casting technique. A 22 × 31 full factorial design was applied to choose the optimized OFDF, utilizing Design-Expert® software (Stat-Ease Inc., Minneapolis, MN, USA). The optimized OFDF (F1) had a 3.89 ± 0.19 Mpa tensile strength, 53.08 ± 1.28% elongation%, 8.12 ± 0.13 MPa Young's modulus, 17.09 ± 1.30 s disintegration time, and 96.02 ± 3.46% PX dissolved after 10 min. This optimized OFDF was subjected to in vitro dissolution, ex vivo permeation, stability, and palatability studies. The permeation study, using chicken buccal pouch, revealed increased drug permeation from the optimized OFDF; with a more than three-fold increase in permeation over the pure drug. The relative bioavailability of the optimized OFDF in comparison with the market tablet was estimated clinically in healthy human volunteers and was found to be 178.43%. These findings confirmed the success of the OFDFs loaded with PX nanosuspension for increasing PX bioavailability.
Collapse
Affiliation(s)
- Ahmed Hassen Elshafeey
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
- Correspondence: ; Tel.: +20-100-584-0261
| | - Rania Moataz El-Dahmy
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Central Axis, Cairo 12585, Egypt;
| |
Collapse
|
9
|
Tylleskar I, Skarra S, Skulberg AK, Dale O. The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers. Eur J Clin Pharmacol 2021; 77:1901-1908. [PMID: 34327552 PMCID: PMC8585821 DOI: 10.1007/s00228-021-03190-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 07/10/2021] [Indexed: 01/16/2023]
Abstract
Purpose Remifentanil has been shown to increase the bioavailability of nasally administered naloxone. The aim of this study was to explore the nature of this observation. Methods We analysed samples from three pharmacokinetic studies to determine the serum concentrations of naloxone-3-glucuronide (N3G), the main metabolite of naloxone, with or without exposure to remifentanil. To enable direct comparison of the three studies, the data are presented as metabolic ratios (ratio of metabolite to mother substance, N3G/naloxone) and dose-corrected values of the area under the curve and maximum concentration (Cmax). Results Under remifentanil exposure, the time to maximum concentration (Tmax) for N3G was significantly higher for intranasal administration of 71 min compared to intramuscular administration of 40 min. The dose-corrected Cmax of N3G after intranasal administration of naloxone under remifentanil exposure was significantly lower (4.5 ng/mL) than in subjects not exposed to remifentanil (7.8–8.4 ng/mL). The metabolic ratios after intranasal administration rose quickly after 30–90 min and were 2–3 times higher at 360 min compared to intravenous and intramuscular administration. Remifentanil exposure resulted in a much slower increase of the N3G/naloxone ratio after intranasal administration compared to intranasal administration with the absence of remifentanil. After remifentanil infusion was discontinued, this effect gradually diminished. From 240 min there was no significant difference between the ratios observed after intranasal naloxone administration. Conclusion Remifentanil increases the bioavailability of naloxone after nasal administration by reducing the pre-systemic metabolism of the swallowed part of the nasal dose. Supplementary Information The online version contains supplementary material available at 10.1007/s00228-021-03190-1.
Collapse
Affiliation(s)
- Ida Tylleskar
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway. .,Clinic of Emergency Medicine and Prehospital Care, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
| | - Sissel Skarra
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway
| | - Arne Kristian Skulberg
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.,Division of Prehospital Services, Oslo University Hospital, Oslo, Norway.,The Norwegian Air Ambulance Foundation, Oslo, Norway
| | - Ola Dale
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway
| |
Collapse
|
10
|
Pikó P, Pál L, Szűcs S, Kósa Z, Sándor J, Ádány R. Obesity-Related Changes in Human Plasma Lipidome Determined by the Lipidyzer Platform. Biomolecules 2021; 11:biom11020326. [PMID: 33669967 PMCID: PMC7924880 DOI: 10.3390/biom11020326] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 02/16/2021] [Accepted: 02/18/2021] [Indexed: 02/07/2023] Open
Abstract
Obesity is an increasing public health concern both in the developed and developing countries. Previous studies have demonstrated that considerable alterations in lipid metabolism and consequently marked changes in lipid profile are associated with the onset and progression of obesity-related complications. To characterize the full spectrum of obesity-induced changes in lipid metabolism, direct infusion tandem mass spectrometry analysis is the most promising approach. To better understand which of the many lipid species are the most strongly associated with obesity, the aim of our work was to measure and profile plasma lipids in normal (n = 57), overweight (n = 31), and obese (n = 48) individuals randomly selected from samples of Hungarian general and Roma populations by using the targeted quantitative lipidomics platform, the Lipidyzer. Principal component and stepwise regression analyses were used to identify the most significant clusters and species of lipids by increasing body mass index (BMI). From the 18 clusters identified four key lipid species (PE P-16:0/20:3, TG 20:4_33:1, TG 22:6_36:4, TG 18:3_33:0) showed a strong significant positive and three others (Hex-Cer 18:1;O2/22:0, LPC 18:2, PC 18:1_18:1) significant negative association with BMI. Compared to individual lipid species alone, the lipid species ratio (LSR) we introduced showed an extremely strong, at least 9 orders of magnitude stronger, association with BMI. The LSR can be used as a sensitive and predictive indicator to monitor obesity-related alterations in human plasma and control the effectiveness of treatment of obesity associated non-communicable diseases.
Collapse
Affiliation(s)
- Péter Pikó
- MTA-DE Public Health Research Group, University of Debrecen, 4032 Debrecen, Hungary;
| | - László Pál
- Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (L.P.); (S.S.); (J.S.)
| | - Sándor Szűcs
- Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (L.P.); (S.S.); (J.S.)
| | - Zsigmond Kósa
- Department of Health Methodology and Public Health, Faculty of Health, University of Debrecen, 4400 Nyíregyháza, Hungary;
| | - János Sándor
- Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (L.P.); (S.S.); (J.S.)
| | - Róza Ádány
- MTA-DE Public Health Research Group, University of Debrecen, 4032 Debrecen, Hungary;
- Department of Public Health and Epidemiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary; (L.P.); (S.S.); (J.S.)
- Correspondence: ; Tel.: +36-52-512-765 (ext. 77408)
| |
Collapse
|
11
|
Leung HH, Leung KS, Durand T, Galano JM, Lee JCY. Measurement of Enzymatic and Nonenzymatic Polyunsaturated Fatty Acid Oxidation Products in Plasma and Urine of Macular Degeneration Using LC-QTOF-MS/MS. Lipids 2020; 55:693-706. [PMID: 32602621 DOI: 10.1002/lipd.12264] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 05/21/2020] [Accepted: 05/22/2020] [Indexed: 11/09/2022]
Abstract
Oxidized polyunsaturated fatty acids (PUFA) are associated to pathogenesis of diseases including cardiovascular and neurodegeneration. The novel products are not only biomarkers but also lipid mediators in gene regulation and signaling pathways. Herein, simultaneous quantitation of 28 products derived from nonenzymatic and enzymatic oxidation of PUFA i.e. 5-, 15-F2t -isoprostanes, 7-, 17-F2t -dihomo-isoprostanes, 7-, 17-F2t -dihomo-isofurans, 5-, 8-, 18-F3t -isoprostanes, 4-, 10-, 13-, 14-, 20-F4t -neuroprostanes, 5-, 8-, 9-, 11-,12-, 15-, 20-HETE, 4-, 7-, 11-, 14-, 17-HDHA, RvE1, and NPD1 using LC-(ESI)-QTOF-MS/MS was developed. These products were measurable in a single sample and the analytical time was relative short (~15 min). Furthermore, we showed that the use of internal standards is a requisite to normalize matrix effects and preparation loss for the quantitation. Validation assays indicated the method to be robust for plasma and mid-stream urine sample analysis in particular from those of age-related macular degeneration subjects, where the accuracy of quantitation displayed good repeatability.
Collapse
Affiliation(s)
- Ho Hang Leung
- School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Pokfulam Road, Hong Kong, Hong Kong SAR
| | - Kin Sum Leung
- School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Pokfulam Road, Hong Kong, Hong Kong SAR
| | - Thierry Durand
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, 5 Av. Charles Flahault, Montpellier, Cedex 05, F34093, France
| | - Jean-Marie Galano
- Institut des Biomolécules Max Mousseron, UMR 5247 CNRS, ENSCM, Université de Montpellier, 5 Av. Charles Flahault, Montpellier, Cedex 05, F34093, France
| | - Jetty Chung-Yung Lee
- School of Biological Sciences, The University of Hong Kong, Pokfulam Road, Pokfulam Road, Hong Kong, Hong Kong SAR
| |
Collapse
|
12
|
Yeun JS, Kan HS, Lee M, Kim N, Oh TY, Nam SK, Choi YS, Kwon IS, Hong JH. Pharmacokinetic comparison of two bazedoxifene acetate 20 mg tablet formulations in healthy Korean male volunteers. Transl Clin Pharmacol 2020; 28:102-108. [PMID: 32656161 PMCID: PMC7327186 DOI: 10.12793/tcp.2020.28.e7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 06/10/2020] [Accepted: 06/10/2020] [Indexed: 12/14/2022] Open
Abstract
Bazedoxifene, used as bazedoxifene acetate, is a selective estrogen receptor modulator that selectively affects the uterus, breast tissue, bone metabolism, and lipid metabolism by antagonizing or enhancing estrogens in the estrogen receptor in the tissue. This study was conducted as an open, randomized, two-period, two-treatment, crossover design to compare the pharmacokinetic (PK) characteristics and tolerability of two bazedoxifene tablets when administered to 50 healthy Korean male volunteers. Enrolled subjects were randomly allocated to 2 sequences of a single oral administration of a test drug and a reference drug, or vice versa with a 14-day washout period between the two doses. Serial blood samples were collected over 96 h for PK analysis. Plasma concentration of bazedoxifene was assayed using liquid chromatography-tandem spectrometry mass. Forty-five participants completed the study with no clinically relevant safety issues. The peak concentrations (Cmax, mean ± strandard deviation) of reference drug and test drug were 3.191 ± 1.080 and 3.231 ± 1.346 ng/mL, respectively, and the areas under the plasma concentration‐time curve from 0 to the last measurable concentration (AUClast) were 44.697 ± 21.168 ng∙h/mL and 45.902 ± 23.130 ng∙h/mL, respectively. The geometric mean ratios of test drug to reference drug and their 90% confidence intervals for Cmax and AUClast were 0.9913 (0.8828–1.1132) and 1.0106 (0.9345–1.0929), respectively. The incidence of adverse events between the two formulations was similar. The present study showed that PK and tolerability of two bazedoxifene tablet formulations were comparable when administered to healthy Korean male volunteers.
Collapse
Affiliation(s)
- Ji-Sun Yeun
- Clinical Trials Center, Chungnam National University Hospital, Daejeon 34134, Korea
| | - Hye-Su Kan
- Center for Infectious Diseases Control, Korea Centers for Disease Control and Prevention, Cheongju 28159, Korea
| | - Minyu Lee
- Huons Co., Ltd, Seongnam 13486, Korea
| | | | | | | | | | - In Sun Kwon
- Clinical Trials Center, Chungnam National University Hospital, Daejeon 34134, Korea
| | - Jang Hee Hong
- Clinical Trials Center, Chungnam National University Hospital, Daejeon 34134, Korea.,Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon 34134, Korea.,Department of Medical Science, College of Medicine, Chungnam National University, Daejeon 34134, Korea
| |
Collapse
|
13
|
Elsayed I, El-Dahmy RM, El-Emam SZ, Elshafeey AH, El Gawad NAA, El-Gazayerly ON. Response surface optimization of biocompatible elastic nanovesicles loaded with rosuvastatin calcium: enhanced bioavailability and anticancer efficacy. Drug Deliv Transl Res 2020; 10:1459-1475. [PMID: 32394333 DOI: 10.1007/s13346-020-00761-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Statins are mainly used for the treatment of hyperlipidemia, but recently, their anticancer role was extremely investigated. The goal of this study was to statistically optimize novel elastic nanovesicles containing rosuvastatin calcium to improve its transdermal permeability, bioavailability, and anticancer effect. The elastic nanovesicles were composed of Tween® 80, cetyl alcohol, and clove oil. The nanodispersions were investigated for their entrapment efficiency, particle size, zeta potential, polydispersity index, and elasticity. The optimized elastic nanovesicular dispersion is composed of 20% cetyl alcohol, 53.47% Tween 80, and 26.53% clove oil. Carboxy methylcellulose was utilized to convert the optimized elastic nanovesicular dispersion into elastic nanovesicular gels. Both the optimized dispersion and the optimized gel (containing 2% w/v carboxymethylcellulose) were subjected to in vitro release study, scanning and transmission electron microscopy, histopathological evaluation, and ex vivo permeation. The cell viability assay of the optimized gel on MCF-7 and Hela cell lines showed significant antiproliferative and potent cytotoxic effects when compared to the drug gel. Moreover, the optimized gel accomplished a significant increase in rosuvastatin bioavailability upon comparison with the drug gel. The optimized gel could be considered as a promising nanocarrier for statins transdermal delivery to increase their systemic bioavailability and anticancer effect. Graphical abstract.
Collapse
|
14
|
Pashaei Y, Daraei B, Shekarchi M. Magnetic-Dispersive Solid Phase Extraction Based on Graphene Oxide-Fe3O4 Nanocomposites Followed by High Performance Liquid Chromatography-Fluorescence for the Preconcentration and Determination of Terazosin Hydrochloride in Human Plasma. J Chromatogr Sci 2020; 58:178-186. [PMID: 31746326 DOI: 10.1093/chromsci/bmz085] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 08/11/2019] [Accepted: 09/18/2019] [Indexed: 11/13/2022]
Abstract
In the present study, a facile modified impregnation method was employed to synthesize superparamagnetic graphene oxide-Fe3O4 (GO-Fe3O4) nanocomposites. Based on the GO-Fe3O4 as adsorbent, a simple and fast magnetic-dispersive solid phase extraction followed by high performance liquid chromatography with fluorescence detection (M-dSPE-HPLC-FL) method was established and validated for the preconcentration and determination of terazosin hydrochloride (TRZ) in human plasma samples. The obtained nanomaterials were characterized by X-ray diffraction, Fourier transform infrared spectroscopy, scanning electron microscopy, energy dispersive X-ray spectroscopy and vibrating sample magnetometry. Different parameters affecting the extraction efficiency, such as sample pH, amount of sorbent, extraction time, elution solvent and its volume and desorption time, were evaluated and optimized. The linearity of the proposed method was excellent over the range 0.3-50.0 ng mL-1 with an acceptable coefficient of determination (R2 = 0.9989). The limit of quantification and limit of detection were found to be 0.3 and 0.09 ng mL-1, respectively, and the preconcentration factor of 10 was achieved. Intra- and inter-day precision expressed as relative standard deviation (RSD %, n = 6) were between 2.2-3.8% and 4.7-6.4%, respectively. Accuracy, estimated by recovery assays, was 97.7-106.6% with RSD ≤ 5.2%. Ultimately, the applicability of the method was successfully confirmed by the extraction and determination of TRZ in human plasma samples.
Collapse
Affiliation(s)
- Yaser Pashaei
- Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Bahram Daraei
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Maryam Shekarchi
- Food and Drug Laboratory Research Center, Food and Drug Organization, MOH & ME, Tehran, Iran
| |
Collapse
|
15
|
Booth B, Vazvaei F, Fluhler E, Myler H, Woolf E. AAPS Workshop Report on ICH M10. AAPS JOURNAL 2019; 22:10. [PMID: 31823177 PMCID: PMC6904406 DOI: 10.1208/s12248-019-0398-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 11/04/2019] [Indexed: 11/30/2022]
Abstract
Over the last decade, several regulatory guidelines on bioanalytical method validation (BMV) have been issued by regulatory agencies around the world. This has left the bioanalytical community struggling with regional differences in regulatory expectations when preparing for global pharmaceutical submissions. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has the mission to achieve greater harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed and registered in the most resource-efficient manner. Following calls for harmonization, ICH-selected bioanalytical method validation and sample analysis among its topics for guidance development and earlier this year released a draft guideline (M10) on BMV for public consultation. In response, the American Association of Pharmaceutical Scientists (AAPS) held a 3-day workshop to provide a forum for regulatory, industry, and academic scientists to discuss the guideline and hear various points of view on key aspects. While there was agreement that the draft guideline is generally well written and comprehensive, specific topics generated considerable discussion and, in some cases, revision recommendations for consideration by the expert working group (EWG) responsible for the guideline content. This report provides a summary of the workshop proceedings.
Collapse
Affiliation(s)
- Brian Booth
- Office of Translational Sciences, Office of Clinical Pharmacology, CDER, US FDA, Silver Spring, Maryland, USA
| | - Faye Vazvaei
- Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, Pennsylvania, USA.
| | - Eric Fluhler
- BA-PK Compliance Associates, LLC, Washingtonville, New York, USA
| | - Heather Myler
- Immunochemistry Department, PPD Laboratories, Richmond, Virginia, USA
| | - Eric Woolf
- Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., West Point, Pennsylvania, USA
| |
Collapse
|
16
|
Vassiliadis S, Elkins AC, Reddy P, Guthridge KM, Spangenberg GC, Rochfort SJ. A Simple LC-MS Method for the Quantitation of Alkaloids in Endophyte-Infected Perennial Ryegrass. Toxins (Basel) 2019; 11:E649. [PMID: 31703425 PMCID: PMC6891275 DOI: 10.3390/toxins11110649] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Revised: 10/25/2019] [Accepted: 11/01/2019] [Indexed: 11/25/2022] Open
Abstract
The rapid identification and quantitation of alkaloids produced by Epichloë endophyte-infected pasture grass is important for the agricultural industry. Beneficial alkaloids, such as peramine, provide the grass with enhanced insect protection. Conversely, ergovaline and lolitrem B can negatively impact livestock. Currently, a single validated method to measure these combined alkaloids in planta does not exist. Here, a simple two-step extraction method was developed for Epichloë-infected perennial ryegrass (Lolium perenne L.). Peramine, ergovaline and lolitrem B were quantified using liquid chromatography-mass spectrometry (LC-MS). Alkaloid linearity, limit of detection (LOD), limit of quantitation (LOQ), accuracy, precision, selectivity, recovery, matrix effect and robustness were all established. The validated method was applied to eight different ryegrass-endophyte symbiota. Robustness was established by comparing quantitation results across two additional instruments; a triple quadruple mass spectrometer (QQQ MS) and by fluorescence detection (FLD). Quantitation results were similar across all three instruments, indicating good reproducibility. LOQ values ranged from 0.8 ng/mL to 6 ng/mL, approximately one hundred times lower than those established by previous work using FLD (for ergovaline and lolitrem B), and LC-MS (for peramine). This work provides the first highly sensitive quantitative LC-MS method for the accurate and reproducible quantitation of important endophyte-derived alkaloids.
Collapse
Affiliation(s)
- Simone Vassiliadis
- Agriculture Victoria, AgriBio Centre for AgriBioscience, Bundoora, VIC 3083, Australia; (A.C.E.); (P.R.); (K.M.G.); (G.C.S.); (S.J.R.)
| | - Aaron C. Elkins
- Agriculture Victoria, AgriBio Centre for AgriBioscience, Bundoora, VIC 3083, Australia; (A.C.E.); (P.R.); (K.M.G.); (G.C.S.); (S.J.R.)
| | - Priyanka Reddy
- Agriculture Victoria, AgriBio Centre for AgriBioscience, Bundoora, VIC 3083, Australia; (A.C.E.); (P.R.); (K.M.G.); (G.C.S.); (S.J.R.)
| | - Kathryn M. Guthridge
- Agriculture Victoria, AgriBio Centre for AgriBioscience, Bundoora, VIC 3083, Australia; (A.C.E.); (P.R.); (K.M.G.); (G.C.S.); (S.J.R.)
| | - German C. Spangenberg
- Agriculture Victoria, AgriBio Centre for AgriBioscience, Bundoora, VIC 3083, Australia; (A.C.E.); (P.R.); (K.M.G.); (G.C.S.); (S.J.R.)
- School of Applied Systems Biology, La Trobe University, Bundoora, VIC 3083, Australia
| | - Simone J. Rochfort
- Agriculture Victoria, AgriBio Centre for AgriBioscience, Bundoora, VIC 3083, Australia; (A.C.E.); (P.R.); (K.M.G.); (G.C.S.); (S.J.R.)
- School of Applied Systems Biology, La Trobe University, Bundoora, VIC 3083, Australia
| |
Collapse
|
17
|
Burger R, Guidi M, Calpini V, Lamoth F, Decosterd L, Robatel C, Buclin T, Csajka C, Marchetti O. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections. J Antimicrob Chemother 2019; 73:3413-3422. [PMID: 30304491 DOI: 10.1093/jac/dky370] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2018] [Accepted: 08/20/2018] [Indexed: 12/15/2022] Open
Abstract
Background Meropenem plasma concentration above a pathogen's MIC over the whole dosing interval (100% ƒT>MIC) is a determinant of outcome in severe infections. Significant variability of meropenem pharmacokinetics is reported in ICU patients. Objectives To characterize meropenem pharmacokinetics in variable CLCR or renal replacement therapy and assess the appropriateness of recommended regimens for MIC coverage. Methods A pharmacokinetic analysis (NONMEM) was conducted with external model validation. Patient characteristics were tested on meropenem clearance estimates, differentiated according to the presence/absence of continuous renal replacement therapy (CRRT, CLCRRT or CLno-CRRT). Simulations evaluated the appropriateness of recommended dosing for achieving 100% fT>MIC in 90% of patients. Results A total of 101 patients were studied: median 63 years (range 49-70), 56% male, SAPS II 38 (27-48). 32% had a CLCR >60 mL/min, 49% underwent CRRT and 32% presented severe sepsis or septic shock. A total of 127 pathogens were documented: 76% Gram-negatives, 24% Gram-positives (meropenem MIC90 2 mg/L, corresponding to EUCAST susceptibility breakpoint). Three hundred and eighty plasma and 129 filtrate-dialysate meropenem concentrations were analysed: two-compartment modelling best described the data. Predicted meropenem CLno-CRRT was 59% lower in impaired (CLCR 30 mL/min) compared to normal (CLCR 100 mL/min) renal function. Simulations showed that recommended regimens appropriately cover MIC90 in patients with CLCR <60 mL/min. Patients with CLCR of 60 to <90 mL/min need 6 g/day to achieve appropriate coverage. In patients with CLCR ≥90 mL/min, appropriate exposure is achieved with increased dose, frequency of administration and infusion duration, or continuous infusion. Conclusions Recommended meropenem regimens are suboptimal in ICU patients with normal or augmented renal clearance. Modified dosing or infusion modalities achieve appropriate MIC coverage for optimized antibacterial efficacy in meropenem-susceptible life-threatening infections.
Collapse
Affiliation(s)
- Raphaël Burger
- Internal Medicine Service, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.,Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Monia Guidi
- Clinical Pharmacology Service, Lausanne University Hospital (CHUV), Lausanne, Switzerland.,School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Valérie Calpini
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Frédéric Lamoth
- Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.,Institute of Microbiology, Department of Laboratories, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Laurent Decosterd
- Clinical Pharmacology Service, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Corinne Robatel
- Clinical Pharmacology Service, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Thierry Buclin
- Clinical Pharmacology Service, Lausanne University Hospital (CHUV), Lausanne, Switzerland
| | - Chantal Csajka
- Clinical Pharmacology Service, Lausanne University Hospital (CHUV), Lausanne, Switzerland.,School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Oscar Marchetti
- Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.,Department of Medicine, Ensemble Hospitalier de la Côte, Morges, Switzerland
| |
Collapse
|
18
|
Mohammad Nejad L, Pashaei Y, Daraei B, Forouzesh M, Shekarchi M. Graphene Oxide-Based Dispersive-Solid Phase Extraction for Preconcentration and Determination of Ampicillin Sodium and Clindamycin Hydrochloride Antibiotics in Environmental Water Samples Followed by HPLC-UV Detection. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR 2019; 18:642-657. [PMID: 31531048 PMCID: PMC6706713 DOI: 10.22037/ijpr.2019.1100676] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
In this work, a reusable graphene oxide (GO) based dispersive-solid phase extraction (d-SPE) was synthesized and used for the analysis of trace ampicillin sodium (AMP) and clindamycin hydrochloride (CLI) in water samples followed by high performance liquid chromatography-UV detection (HPLC-UV). Batch experiments were conducted to investigate the effects of pH and volume of the sample solution, contact time, adsorption isotherms, temperature, and desorption conditions. The maximum adsorption capacities of AMP and CLI on GO nanosheets were found to be 33.33 mg g-1 and 47 mg g-1, respectively. The adsorption isotherm data can be well fitted by Temkin (AMP and CLI) and Freundlich (AMP), and the adsorption process followed the pseudo-second-order model. The thermodynamic parameters were calculated, indicated that the adsorption process of both analytes were spontaneous and exothermic. In addition, the d-SPE following HPLC analyses showed good linearity in the range of 0.5-200 ng mL-1 (R2= 0.999) for AMP and 1-200 ng mL-1 (R2= 0.999) for CLI, with LOD of 0.04 and 0.24 ng mL-1 for AMP and CLI, respectively. The percent of extraction recoveries, intra and inter-day precisions (expressed as RSD %, n = 3) were in the range of 96.4-101.6%, 2.2-3.0, and 3.7-4.7 for AMP as well as 94.2-98.6%, 2.2-3.8, and 3.5-4.6 for CLI, respectively. The preconcentration factor of 20 was achieved for both analytes. From these results, it can be concluded that the validated method is a simple, cost-effective and repeatable method for analysis of AMP and CLI in water samples and provide a new platform for antibiotics decontamination.
Collapse
Affiliation(s)
- Leila Mohammad Nejad
- Department of Toxicology, Faculty of Medical Sciences, Tarbiat Modares University Tehran, Iran
| | - Yaser Pashaei
- Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Bahram Daraei
- Department of Toxicology and Pharmacology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mehdi Forouzesh
- Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran
| | - Maryam Shekarchi
- Food and Drug Laboratory Research Center, Food and Drug Organization, MOH & ME, Tehran, Iran
| |
Collapse
|
19
|
Courlet P, Spaggiari D, Desfontaine V, Cavassini M, Alves Saldanha S, Buclin T, Marzolini C, Csajka C, Decosterd LA. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1125:121733. [PMID: 31374423 DOI: 10.1016/j.jchromb.2019.121733] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Revised: 07/02/2019] [Accepted: 07/24/2019] [Indexed: 11/17/2022]
Abstract
Thanks to highly active antiretroviral treatments, HIV infection is now considered as a chronic condition. Consequently, people living with HIV (PLWH) live longer and encounter more age-related chronic co-morbidities, notably cardiovascular diseases, leading to polypharmacy. As the management of drug-drug interactions (DDIs) constitutes a key aspect of the care of PLWH, the magnitude of pharmacokinetic DDIs between cardiovascular and anti-HIV drugs needs to be more thoroughly characterized. To that endeavour, an UHPLC-MS/MS bioanalytical method has been developed for the simultaneous determination in human plasma of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin and its active metabolites. Plasma samples were subjected to protein precipitation with methanol, followed by evaporation at room temperature under nitrogen of the supernatant, allowing to attain measurable plasma concentrations down to sub-nanogram per milliliter levels. Stable isotope-labelled analytes were used as internal standards. The five drugs and two metabolites were analyzed using a 6-min liquid chromatographic run coupled to electrospray triple quadrupole mass spectrometry detection. The method was validated over the clinically relevant concentrations ranging from 0.3 to 480 ng/mL for amlodipine, atorvastatin and p-OH-atorvastatin, and 0.4 to 480 ng/mL for pravastatin, 0.5 to 480 ng/mL for rosuvastatin and o-OH-atorvastatin, and 3 to 4800 ng/mL for metoprolol. Validation performances such as trueness (95.4-110.8%), repeatability (1.5-13.4%) and intermediate precision (3.6-14.5%) were in agreement with current international recommendations. Accuracy profiles (total error approach) were lying within the limits of ±30% accepted in bioanalysis. This rapid and robust UHPLC-MS/MS assay allows the simultaneous quantification in plasma of the major currently used cardiovascular drugs and offers an efficient analytical tool for clinical pharmacokinetics as well as DDIs studies.
Collapse
Affiliation(s)
- Perrine Courlet
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Switzerland.
| | - Dany Spaggiari
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Switzerland.
| | - Vincent Desfontaine
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Switzerland.
| | - Matthias Cavassini
- Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Switzerland.
| | - Susana Alves Saldanha
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Switzerland.
| | - Thierry Buclin
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Switzerland.
| | - Catia Marzolini
- Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Switzerland.
| | - Chantal Csajka
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Switzerland; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Switzerland.
| | - Laurent-Arthur Decosterd
- Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Switzerland.
| |
Collapse
|
20
|
Elsayed I, El-Dahmy RM, Elshafeey AH, Abd El Gawad NA, El Gazayerly ON. Tripling the Bioavailability of Rosuvastatin Calcium Through Development and Optimization of an In-Situ Forming Nanovesicular System. Pharmaceutics 2019; 11:E275. [PMID: 31212660 PMCID: PMC6631901 DOI: 10.3390/pharmaceutics11060275] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 05/06/2019] [Accepted: 06/06/2019] [Indexed: 12/20/2022] Open
Abstract
In situ forming nanovesicular systems (IFNs) were prepared and optimized to improve Rosuvastatin calcium (RC) oral bioavailability through increasing its solubility and dissolution rate. The IFN was composed of Tween® 80 (T80), cetyl alcohol (CA), in addition to mannitol or Aerosil 200. A single simple step was adopted for preparation, then the prepared formulations were investigated by analyzing their particle size (PS), polydispersity index (PDI), Zeta potential (ZP), entrapment efficiency (EE), and flowability properties. D-optimal design was applied to choose the optimized formulations. The maximum desirability values were 0.754 and 0.478 for the optimized formulations containing 0.05 g CA, 0.18 g T80, and 0.5 g mannitol (OFM) or Aerosil (OFA), respectively. In vitro drug release from the optimized formulations showed a significantly faster dissolution rate when compared to the market product. In vivo performance of the optimized formulations in rabbits was investigated after filling them into enteric-coated capsules. Ultimately, OFA formulation achieved a 3 times increase in RC oral bioavailability in comparison with the market product, supporting the hypothesis of considering IFNs as promising nanocarriers able to boost the bioavailability of BCS class II drugs.
Collapse
Affiliation(s)
- Ibrahim Elsayed
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
- Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman 4184, UAE.
| | - Rania Moataz El-Dahmy
- Department of Pharmaceutics, Faculty of Pharmacy, October 6 University, Cairo 12585, Egypt.
| | - Ahmed Hassen Elshafeey
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
| | - Nabaweya Abdelaziz Abd El Gawad
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
- Department of Pharmaceutics, Faculty of Pharmacy, October 6 University, Cairo 12585, Egypt.
| | - Omaima Naim El Gazayerly
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
| |
Collapse
|
21
|
Fast LC-MS quantitation of glucose and glycerol via enzymatic derivatization. Anal Biochem 2019; 575:40-43. [PMID: 30940446 DOI: 10.1016/j.ab.2019.03.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 03/26/2019] [Accepted: 03/27/2019] [Indexed: 11/21/2022]
Abstract
Glucose and glycerol are important circulating metabolites. Due to poor ionization and/or ion suppression, the liquid chromatography-mass spectrometry (LC-MS) detection of glucose and glycerol presents challenges. Here, we propose an efficient LC-MS method of quantitative glucose and glycerol detection via enzymatic derivatization to glucose-6-phosphate and sn-glycerol-3-phosphate, respectively. This derivatization protocol can be used to measure the concentrations of glucose production in a plethora of sample types for metabolic analysis and is compatible with the general metabolomics workflow. This novel approach allows us to quantitatively study glucose and glycerol metabolism using stable isotope tracers in vivo.
Collapse
|
22
|
Alam MA, Abou Obaid NI, Ibrahim MA, Raish M, Al-Jenoobi FI. A Validated Ultra-Performance Liquid Chromatography Tandem Triple Quadrupole Mass Spectrometric Method for Fast Determination of Losartan in Rabbit Plasma. J Chromatogr Sci 2019; 57:323-330. [DOI: 10.1093/chromsci/bmy114] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 12/16/2018] [Accepted: 12/24/2018] [Indexed: 11/14/2022]
Affiliation(s)
- Mohd Aftab Alam
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh-11451, Saudi Arabia
| | - Nuha Ibrahim Abou Obaid
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh-11451, Saudi Arabia
| | - Mohamed Abbas Ibrahim
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh-11451, Saudi Arabia
- Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Al-Azhar University, Assiut, Egypt
| | - Mohammad Raish
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh-11451, Saudi Arabia
| | - Fahad Ibrahim Al-Jenoobi
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh-11451, Saudi Arabia
| |
Collapse
|
23
|
Li Q, Zhang H, Zhu X, Liu C, Wu M, Li C, Li X, Gao L, Ding Y. Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients. Front Pharmacol 2018; 9:1372. [PMID: 30559662 PMCID: PMC6284260 DOI: 10.3389/fphar.2018.01372] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2018] [Accepted: 11/08/2018] [Indexed: 11/20/2022] Open
Abstract
Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients. Methods: Three randomized, open-label, two-period crossover bioequivalence studies were conducted with albumin-bound paclitaxel. Each subject received a single dose of 260 mg/m2 albumin-bound paclitaxel [sponsor 1 (QL, light food), sponsor 2 (HR, fasting), sponsor 3 (ZDTQ, light food); test] or Abraxane® (reference) and was monitored for 72 h. Serum concentrations of total paclitaxel and unbound paclitaxel were measured using liquid chromatography/mass spectrometry (LC/MS), and appropriate pharmacokinetic parameters were determined by non-compartmental methods. Safety assessments included adverse events, hematology and biochemistry tests. Results: The bioequivalence analyses of the QL, HR, and ZDTQ products included 24, 23, and 24 patients, respectively. The mean t1/2 was 20.61–27.31 h for total paclitaxel. Food intake did not affect the pharmacokinetics of paclitaxel. From the comparison of total paclitaxel and unbound paclitaxel, the 90% confidence intervals (CIs) for the ratios of Cmax, AUC0−t, and AUC0−∞ were within 80.00–125.00%. The intra-subject variability ranged from 6.4–11% to 9.85–15.87% for total paclitaxel and unbound paclitaxel, respectively. Almost all subjects in the test and Abraxane® (reference) groups experienced mild or moderate adverse events. No fatal AEs or study drug injection site reactions related to these drugs were observed. Conclusion: Albumin-bound paclitaxel (QL, HR or ZDTQ; test products) showed bioequivalence to Abraxane® (reference) with lower intra-subject variability, which was less than 16% in all cases, and was well-tolerated in Chinese breast cancer patients. Twenty-two patients are enough for an albumin-bound paclitaxel bioequivalence study.
Collapse
Affiliation(s)
- Qingmei Li
- The First Hospital of Jilin University, Changchun, China
| | - Hong Zhang
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| | - Xiaoxue Zhu
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| | - Chengjiao Liu
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| | - Min Wu
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| | - Cuiyun Li
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| | - Xiaojiao Li
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| | - Lei Gao
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| | - Yanhua Ding
- Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China
| |
Collapse
|
24
|
El-Serafi I, Loy O, Zhao Y, Oerther S, Mattsson J. Pre-formulation investigations for establishing a protocol for treosulfan handling and activation. Pharm Dev Technol 2018; 24:639-648. [PMID: 30474459 DOI: 10.1080/10837450.2018.1551903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION Treosulfan is an alkylating agent that is used for the treatment of ovarian cancer and for conditioning prior to stem cell transplantation. It is a prodrug that is activated non-enzymatically to two active epoxides. OBJECTIVES To optimize a protocol for both in vivo samples handling and in vitro drug preparation. Treosulfan stability was tested in biological fluids at different conditions as well as for its cytotoxicity on cell lines. RESULTS Plasma samples can be safely frozen for a short period up to 8 h, however; for longer periods, samples should be acidified. Urine samples and cell culture media can be safely frozen regardless their pH. For in vitro investigations, incubation of treosulfan at 37 °C for 24 h activated 100% of the drug. Whole blood acidification should be avoided for the risk of hemolysis. Finally; treosulfan cytotoxicity on HL-60 cells has increased following pre-incubation for 24 h at 37 °C compared to K562 cell line. CONCLUSION The stability profiling of treosulfan provided a valuable reference for handling of biological samples for both in vivo and in vitro studies. These results can be utilized for further investigations concerning the drug kinetics and dynamics in addition to the development of new pharmaceutical formulations.
Collapse
Affiliation(s)
- Ibrahim El-Serafi
- a Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden.,b Department of Clinical and Experimental Medicine , Linköping University , Linköping , Sweden.,c Department of Biochemistry, Faculty of Medicine , Port-Said University, Port-Said , Egypt
| | - Orlaith Loy
- a Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden
| | - Ying Zhao
- a Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden
| | - Sandra Oerther
- a Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden
| | - Jonas Mattsson
- d Department of Oncology and Pathology , Karolinska Institutet , Stockholm , Sweden.,e Department of Hematology , Oslo University Hospital , Oslo , Norway
| |
Collapse
|
25
|
Carvalho J, Rosado T, Barroso M, Gallardo E. Determination of Antiepileptic Drugs Using Dried Saliva Spots. J Anal Toxicol 2018; 43:61-71. [DOI: 10.1093/jat/bky064] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Indexed: 01/24/2023] Open
Affiliation(s)
- Joana Carvalho
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, Covilhã, Portugal
| | - Tiago Rosado
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, Covilhã, Portugal
- Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, EM506, Covilhã, Portugal
| | - Mário Barroso
- Instituto Nacional de Medicina Legal e Ciências Forenses – Delegação do Sul, Rua Manuel Bento de Sousa, 3, Lisboa, Portugal
| | - Eugenia Gallardo
- Centro de Investigação em Ciências da Saúde (CICS-UBI), Universidade da Beira Interior, Av. Infante D. Henrique, Covilhã, Portugal
- Laboratório de Fármaco-Toxicologia, UBIMedical, Universidade da Beira Interior, EM506, Covilhã, Portugal
| |
Collapse
|
26
|
Tylleskar I, Skulberg AK, Skarra S, Nilsen T, Dale O. Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil. Eur J Clin Pharmacol 2018; 74:1547-1553. [PMID: 30143830 DOI: 10.1007/s00228-018-2545-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2018] [Accepted: 08/16/2018] [Indexed: 01/03/2023]
Abstract
PURPOSE Pharmacodynamic studies of naloxone require opioid agonism. Steady state condition may be achieved by remifentanil TCI (target controlled infusion). Opioid agonism can be measured by pupillometry. It is not known whether there are arteriovenous concentration differences for naloxone. The aim was thus to further develop a model for studying pharmacokinetic/pharmacodynamic aspects of naloxone and to explore whether a significant arteriovenous concentration difference for naloxone in humans was present. METHODS Relevant authorities approved this study. Healthy volunteers (n = 12) were given 1.0 mg intravenous (IV) naloxone after steady state opioid agonism was obtained by TCI of remifentanil (1.3 ng/ml). Opioid effect was measured by pupillometry. Arterial and venous samples were collected simultaneously before and for 2 h after naloxone administration for quantification of naloxone and remifentanil. RESULTS Arterial remifentanil was in steady state at 12 min. One milligram IV naloxone reversed the effect of remifentanil to 93% of pre-opioid pupil-size within 4 min. The estimated duration of antagonism was 118 min. At that time, the concentration of naloxone was 0.51 ng/ml. The time course of arterial and venous serum concentrations for naloxone was similar, although arterial AUC (area under the curve) was slightly lower (94%) than the venous AUC (p = 0.03). There were no serious adverse events. CONCLUSION Onset of reversal by IV naloxone was rapid and lasted 118 min. The minimum effective concentration was 0.5 ng/ml. Using TCI remifentanil to obtain a steady-state opioid agonism may be a useful tool to compare new naloxone products.
Collapse
Affiliation(s)
- Ida Tylleskar
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.,Clinic of Emergency Medicine and Prehospital Care, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway
| | - Arne Kristian Skulberg
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway.,Division of Emergencies and Critical Care, Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway
| | - Sissel Skarra
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway
| | - Turid Nilsen
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway
| | - Ola Dale
- Department of Circulation and Medical Imaging, NTNU - Norwegian University of Science and Technology, Trondheim, Norway. .,Department of Research and Development, St. Olavs hospital, Trondheim University Hospital, Trondheim, Norway.
| |
Collapse
|
27
|
Toward decision-based acceptance criteria for Bioanalytical Method Validation: a proposal for discussion from the European Bioanalysis Forum. Bioanalysis 2018; 10:1255-1259. [DOI: 10.4155/bio-2018-0131] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
28
|
Alladio E, Biosa G, Seganti F, Di Corcia D, Salomone A, Vincenti M, Baumgartner MR. Systematic optimisation of ethyl glucuronide extraction conditions from scalp hair by design of experiments and its potential effect on cut-off values appraisal. Drug Test Anal 2018; 10:1394-1403. [DOI: 10.1002/dta.2405] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 04/04/2018] [Accepted: 05/01/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Eugenio Alladio
- Centro Regionale Antidoping ‘A. Bertinaria’; Turin Italy
- Dipartimento di Chimica; Universita` degli Studi di Torino; Turin Italy
| | - Giulia Biosa
- Dipartimento di Chimica; Universita` degli Studi di Torino; Turin Italy
| | | | | | | | - Marco Vincenti
- Centro Regionale Antidoping ‘A. Bertinaria’; Turin Italy
- Dipartimento di Chimica; Universita` degli Studi di Torino; Turin Italy
| | | |
Collapse
|
29
|
Courlet P, Spaggiari D, Cavassini M, Du Pasquier R, Alves Saldanha S, Buclin T, Marzolini C, Csajka C, Decosterd L. Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. CLINICAL MASS SPECTROMETRY (DEL MAR, CALIF.) 2018; 8:8-20. [PMID: 39192990 PMCID: PMC11322778 DOI: 10.1016/j.clinms.2018.04.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Revised: 04/18/2018] [Accepted: 04/24/2018] [Indexed: 12/12/2022]
Abstract
Nucleoside reverse transcriptase inhibitors (NRTIs) have been the first class of antiretroviral drugs used against HIV infection. Despite NRTI-free regimens have been eagerly sought over the years in an effort for treatment simplification, NRTIs remain in most antiretroviral combination treatment. There has been generally a limited interest for their therapeutic drug monitoring, arguably because NRTIs levels measured in plasma poorly predict the concentration of pharmacologically active metabolites in cells. Plasma concentrations do impact cellular levels, while large differences between NRTIs have been found with regard to their ability to distribute into the cerebrospinal fluid (CSF) compartment. The renewed interest for the measurements of NRTIs concentrations in plasma and CSF was raised by ongoing efforts to understand some instances of toxicity or for determining their actual implication in the development of HIV-associated neurological disorders. In this context, a 5-min multiplex ultra-high-pressure chromatography tandem mass spectrometry (UHPLC-MS/MS) analysis in human plasma and CSF was developed for NRTIs used in clinical practice: abacavir, emtricitabine, lamivudine, tenofovir and zidovudine along with zidovudine glucuronide (Gln-ZDV). The 200-fold dilution of blank human plasma was shown to be a reliable surrogate matrix for quantification of NRTIs and Gln-ZDV in CSF. Both methodologies were fully validated over the clinically relevant concentrations, and satisfactorily fulfilled all parameters for bioanalytical methods validation. This sensitive, rapid, and robust UHPLC-MS/MS assay offers a methodology for increasing our understanding of the ability of NRTIs to cross the blood-brain barrier and their potential implication in neuropsychological disorders observed in HIV-infected patients.
Collapse
Affiliation(s)
- Perrine Courlet
- Laboratory and Service of Clinical Pharmacology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Dany Spaggiari
- Laboratory and Service of Clinical Pharmacology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Matthias Cavassini
- Service of Infectious Diseases, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Renaud Du Pasquier
- Service of Neurology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Susana Alves Saldanha
- Laboratory and Service of Clinical Pharmacology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Thierry Buclin
- Service of Clinical Pharmacology, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Catia Marzolini
- Departments of Medicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland
| | - Chantal Csajka
- Service of Clinical Pharmacology, University Hospital and University of Lausanne, Lausanne, Switzerland
- School of Pharmacy, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Laurent Decosterd
- Laboratory and Service of Clinical Pharmacology, University Hospital and University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
30
|
El-Refai K, Teaima MH, El-Nabarawi MA. Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative pharmacokinetic study in healthy human subjects. Drug Dev Ind Pharm 2018; 44:988-1000. [DOI: 10.1080/03639045.2018.1427761] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Khaled El-Refai
- Central Administration of Pharmaceutical Affairs (CAPA), Cairo, Egypt
| | - Mahmoud H. Teaima
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Mohamed A. El-Nabarawi
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| |
Collapse
|
31
|
Determination of isoquercitrin in rat plasma by high performance liquid chromatography coupled with a novel synergistic cloud point extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1072:136-141. [DOI: 10.1016/j.jchromb.2017.11.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Revised: 08/03/2017] [Accepted: 11/10/2017] [Indexed: 11/22/2022]
|
32
|
Panda SS, Sharma K, Mohanty B, Bera RKVV, Acharjya SK, Beg S. Integrated quality by design (QbD) and design of experiments (DoE) approach for UFLC determination of telaprevir in rat serum. J LIQ CHROMATOGR R T 2017. [DOI: 10.1080/10826076.2017.1387558] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Sagar Suman Panda
- Department of Pharmaceutical Analysis & Quality Assurance, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
| | - Khusbu Sharma
- Department of Pharmaceutical Analysis & Quality Assurance, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
| | - Bijeta Mohanty
- Department of Pharmaceutical Analysis & Quality Assurance, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
| | - Ravi Kumar Venkata Varaha Bera
- Department of Pharmaceutical Analysis & Quality Assurance, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
| | - Sasmita Kumari Acharjya
- Department of Pharmaceutical Analysis & Quality Assurance, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
| | - Sarwar Beg
- Product Development Research, Jubilant Generics Ltd., Noida, Uttar Pradesh, India
| |
Collapse
|
33
|
El-Serafi I, Terelius Y, Abedi-Valugerdi M, Naughton S, Saghafian M, Moshfegh A, Mattsson J, Potácová Z, Hassan M. Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. PLoS One 2017; 12:e0187294. [PMID: 29121650 PMCID: PMC5679629 DOI: 10.1371/journal.pone.0187294] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 10/17/2017] [Indexed: 12/21/2022] Open
Abstract
Busulphan (Bu) is an alkylating agent used in the conditioning regimen prior to hematopoietic stem cell transplantation (HSCT). Bu is extensively metabolized in the liver via conjugations with glutathione to form the intermediate metabolite (sulfonium ion) which subsequently is degraded to tetrahydrothiophene (THT). THT was reported to be oxidized forming THT-1-oxide that is further oxidized to sulfolane and finally 3-hydroxysulfolane. However, the underlying mechanisms for the formation of these metabolites remain poorly understood. In the present study, we performed in vitro and in vivo investigations to elucidate the involvement of flavin-containing monooxygenase-3 (FMO3) and cytochrome P450 enzymes (CYPs) in Bu metabolic pathway. Rapid clearance of THT was observed when incubated with human liver microsomes. Furthermore, among different recombinant microsomal enzymes, the highest intrinsic clearance for THT was obtained via FMO3 followed by several CYPs including 2B6, 2C8, 2C9, 2C19, 2E1 and 3A4. In Bu- or THT-treated mice, inhibition of FMO3 by phenylthiourea significantly suppressed the clearance of both Bu and THT. Moreover, the simultaneous administration of a high dose of THT (200μmol/kg) to Bu-treated mice reduced the clearance of Bu. Consistently, in patients undergoing HSCT, repeated administration of Bu resulted in a significant up-regulation of FMO3 and glutathione-S-transfrase -1 (GSTA1) genes. Finally, in a Bu-treated patient, additional treatment with voriconazole (an antimycotic drug known as an FMO3-substrate) significantly altered the Bu clearance. In conclusion, we demonstrate for the first time that FMO3 along with CYPs contribute a major part in busulphan metabolic pathway and certainly can affect its kinetics. The present results have high clinical impact. Furthermore, these findings might be important for reducing the treatment-related toxicity of Bu, through avoiding interaction with other concomitant used drugs during conditioning and hence improving the clinical outcomes of HSCT.
Collapse
Affiliation(s)
- Ibrahim El-Serafi
- Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
| | - Ylva Terelius
- Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
| | - Manuchehr Abedi-Valugerdi
- Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
| | - Seán Naughton
- Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
| | - Maryam Saghafian
- Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden
| | - Ali Moshfegh
- Cancer Center of Karolinska (CCK), Department of Oncology-Pathology, Karolinska Institutet, Solna, Stockholm, Sweden
| | - Jonas Mattsson
- Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital-Huddinge, Stockholm, Sweden.,Department of Oncology and Pathology, Karolinska Institutet, Solna, Stockholm, Sweden
| | - Zuzana Potácová
- Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden.,ECM, Clinical Research Centre (KFC), Novum, Karolinska University Hospital, Huddinge, Sweden
| | - Moustapha Hassan
- Experimental Cancer Medicine (ECM), Clinical Research Centre (KFC), Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden.,ECM, Clinical Research Centre (KFC), Novum, Karolinska University Hospital, Huddinge, Sweden
| |
Collapse
|
34
|
Scholman RC, Giovannone B, Hiddingh S, Meerding JM, Malvar Fernandez B, van Dijk MEA, Tempelman MJ, Prakken BJ, de Jager W. Effect of anticoagulants on 162 circulating immune related proteins in healthy subjects. Cytokine 2017; 106:114-124. [PMID: 29089178 DOI: 10.1016/j.cyto.2017.10.021] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Revised: 08/10/2017] [Accepted: 10/23/2017] [Indexed: 10/18/2022]
Abstract
Diagnosis of complex disease and response to treatment is often associated with multiple indicators, both clinical and laboratorial. With the use of biomarkers, various mechanisms have been unraveled which can lead to better and faster diagnosis, predicting and monitoring of response to treatment and new drug development. With the introduction of multiplex technology for immunoassays and the growing awareness of the role of immune-monitoring during new therapeutic interventions it is now possible to test large numbers of soluble mediators in small sample volumes. However, standardization of sample collection and laboratory assessments remains suboptimal. We developed a multiplex immunoassay for detection of 162 immune related proteins in human serum and plasma. The assay was split in panels depending on natural occurring concentrations with a maximum of 60 proteins. The aim of this study was to evaluate precision, accuracy, reproducibility and stability of proteins when repeated freeze-thaw cycles are performed of this in-house developed panel, as well as assessing the protein signature in plasma and serum using various anticoagulants. Intra-assay variance of each mediator was <10%. Inter-assay variance ranged between 1.6 and 37% with an average of 12.2%. Recoveries were similar for all mediators (mean 99.8 ± 2.6%) with a range between 89-107%. Next we measured all mediators in serum, EDTA plasma and sodium heparin plasma of 43 healthy control donors. Of these markers only 19 showed similar expression profiles in the 3 different matrixes. Only 5 mediators were effected by multiple freeze-thawing cycles. Principal component analysis revealed different coagulants cluster separately and that sodium heparin shows the most consistent profile.
Collapse
Affiliation(s)
- Rianne C Scholman
- Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Barbara Giovannone
- Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands; Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Sanne Hiddingh
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Jenny M Meerding
- Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Beatriz Malvar Fernandez
- Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Mariska E A van Dijk
- Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Mariëlle J Tempelman
- Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Berent J Prakken
- Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands
| | - Wilco de Jager
- Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands; Multiplex Core Facility, Laboratory of Translational Immunology, University Medical center Utrecht, Utrecht, The Netherlands.
| |
Collapse
|
35
|
Panda SS, Sharma K, Mohanty B, Bera RKVV, Acharjya SK, Chowdhury B. Quality by Design enabled enhanced bioanalytical extraction and UFLC determination of vilazodone from rat serum. J LIQ CHROMATOGR R T 2017. [DOI: 10.1080/10826076.2017.1360908] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Sagar Suman Panda
- Department of Pharmaceutical Analysis and Quality Assurance, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Odisha, India
| | - Khusbu Sharma
- Department of Pharmaceutical Analysis and Quality Assurance, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Odisha, India
| | - Bijeta Mohanty
- Department of Pharmaceutical Analysis and Quality Assurance, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Odisha, India
| | - Ravi kumar Venkata Varaha Bera
- Department of Pharmaceutical Analysis and Quality Assurance, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Odisha, India
| | - Sasmita Kumari Acharjya
- Department of Pharmaceutical Analysis and Quality Assurance, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Odisha, India
| | - Bimalendu Chowdhury
- Department of Pharmacology, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Odisha, India
| |
Collapse
|
36
|
Mendes E, Acetturi BG, Thomas AM, Martins FDS, Crisma AR, Murata G, Braga TT, Camâra NOS, Franco ALDS, Setubal JC, Ribeiro WR, Valduga CJ, Curi R, Dias-Neto E, Tavares-de-Lima W, Ferreira CM. Prophylactic Supplementation of Bifidobacterium longum 5 1A Protects Mice from Ovariectomy-Induced Exacerbated Allergic Airway Inflammation and Airway Hyperresponsiveness. Front Microbiol 2017; 8:1732. [PMID: 28959241 PMCID: PMC5604069 DOI: 10.3389/fmicb.2017.01732] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Accepted: 08/24/2017] [Indexed: 12/14/2022] Open
Abstract
Asthma is a chronic inflammatory disease that affects more females than males after puberty, and its symptoms and severity in women change during menstruation and menopause. Recently, evidence has demonstrated that interactions among the microbiota, female sex hormones, and immunity are associated with the development of autoimmune diseases. However, no studies have investigated if therapeutic gut microbiota modulation strategies could affect asthma exacerbation during menstruation and menopause. Here we aimed to examine the preventive effects of a probiotic, Bifidobacterium longum 51A, on airway inflammation exacerbation in allergic ovariectomized mice. We first evaluated the gut microbiota composition and diversity in mice 10 days after ovariectomy. Next, we examined whether re-exposure of ovariectomized allergic mice to antigen (ovalbumin) would lead to exacerbation of lung inflammation. Finally, we evaluated the preventive and treatment effect of B. longum 51A on lung inflammation and airway hyperresponsiveness. Our results showed that whereas ovariectomy caused no alterations in the gut microbiota composition and diversity in this animal model, 10 days after ovariectomy, preventive use administration of B. longum 51A, rather than its use after surgery was capable of attenuate the exacerbated lung inflammation and hyperresponsiveness in ovariectomized allergic mice. This prophylactic effect of B. longum 51A involves acetate production, which led to increased fecal acetate levels and, consequently, increased Treg cells in ovariectomized allergic mice.
Collapse
Affiliation(s)
- Eduardo Mendes
- Department of Pharmaceutics Sciences, Institute of Environmental, Chemistry and Pharmaceutical Sciences, Universidade Federal de São PauloDiadema, Brazil
| | - Beatriz G Acetturi
- Department of Pharmacology, Institute of Biomedical Sciences I, University of São PauloSão Paulo, Brazil
| | - Andrew M Thomas
- Medical Genomics Laboratory, CIPE/A.C.Camargo Cancer CenterSão Paulo, Brazil.,Department of Biochemistry, Institute of Chemistry, University of São PauloSão Paulo, Brazil.,Bioinformatics Graduate Program, University of São PauloSão Paulo, Brazil
| | - Flaviano Dos S Martins
- Department of Microbiology, Institute of Biological Sciences, Federal University of Minas GeraisBelo Horizonte, Brazil
| | - Amanda R Crisma
- Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São PauloSão Paulo, Brazil
| | - Gilson Murata
- Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São PauloSão Paulo, Brazil
| | - Tárcio T Braga
- Department of Immunology, Institute of Biomedical Sciences IV, University of São PauloSão Paulo, Brazil
| | - Niels O S Camâra
- Department of Immunology, Institute of Biomedical Sciences IV, University of São PauloSão Paulo, Brazil
| | - Adriana L Dos S Franco
- Post Graduate Program in Biophotonics Applied to Health Sciences, Universidade Nove de JulhoSão Paulo, Brazil
| | - João C Setubal
- Department of Biochemistry, Institute of Chemistry, University of São PauloSão Paulo, Brazil
| | - Willian R Ribeiro
- Department of Pharmaceutics Sciences, Institute of Environmental, Chemistry and Pharmaceutical Sciences, Universidade Federal de São PauloDiadema, Brazil
| | - Claudete J Valduga
- Department of Pharmacy and Biotechnology, Universidade de Anhanguera de São PauloSão Paulo, Brazil
| | - Rui Curi
- Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São PauloSão Paulo, Brazil
| | - Emmanuel Dias-Neto
- Medical Genomics Laboratory, CIPE/A.C.Camargo Cancer CenterSão Paulo, Brazil.,Laboratory of Neurosciences (LIM-27), Institute of Psychiatry, Medical School University of São PauloSão Paulo, Brazil
| | - Wothan Tavares-de-Lima
- Department of Pharmacology, Institute of Biomedical Sciences I, University of São PauloSão Paulo, Brazil
| | - Caroline M Ferreira
- Department of Pharmaceutics Sciences, Institute of Environmental, Chemistry and Pharmaceutical Sciences, Universidade Federal de São PauloDiadema, Brazil
| |
Collapse
|
37
|
Ting CT, Cheng YY, Tsai TH. Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats. Molecules 2017; 22:E1034. [PMID: 28640225 PMCID: PMC6152211 DOI: 10.3390/molecules22071034] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2017] [Accepted: 06/19/2017] [Indexed: 12/12/2022] Open
Abstract
Sorafenib has been used as a standard therapy for advanced hepatocellular carcinoma (HCC). In Asia, patients with HCC are potentially treated with the combination of sorafenib and Chinese herbal medicines to improve the efficiency and reduce the side effects of sorafenib. However, limited information about the herb-drug interactions is available. We hypothesize that the Chinese herbal medicine may exert hepatoprotective effects on the sorafenib-treated group. The aim of this study is to investigate the pharmacokinetic mechanism of drug-drug interactions of sorafenib including interacting with hepatoprotective formulation, Long-Dan-Xie-Gan-Tang formulation (LDXGT) and with two cytochrome P450 3A4 (CYP3A4) inhibitors, grapefruit juice and ketoconazole. Liver enzyme levels and histopathology of liver slices were used to evaluate sorafenib-induced hepatotoxicity and the potential hepatoprotective effects of the LDXGT formulation on subjects treated with the combination of sorafenib and the herbal medicine. In this study, a validated HPLC-photodiode array analytical system was developed for the pharmacokinetic study of sorafenib in rats. As the result of the pharmacokinetic data, pretreatment with the LDXGT formulation did not significantly interact with sorafenib compared with sorafenib oral administration alone. Furthermore, grapefruit juice and ketoconazole did not significantly affect sorafenib metabolism. Furthermore, pretreatment with variable, single or repeat doses of the LDXGT formulation did not suppress or exacerbate the sorafenib-induced hepatotoxicity and histopathological alterations. According to these results, the LDXGT formulation is safe, but has no beneficial effects on sorafenib-induced hepatotoxicity. A detailed clinical trial should be performed to further evaluate the efficacy or adverse effects of the LDXGT formulation in combination with sorafenib in humans.
Collapse
Affiliation(s)
- Chin-Tsung Ting
- Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
- Division of Gastrointestinal Surgery, Department of Surgery, Ren-Ai Branch, Taipei City Hospital, Taipei 10629, Taiwan.
| | - Yung-Yi Cheng
- Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
| | - Tung-Hu Tsai
- Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan.
- Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan.
- School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
- Department of Chemical Engineering, National United University, Miaoli 36063, Taiwan.
| |
Collapse
|
38
|
Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O. Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol 2017; 73:555-562. [PMID: 28144724 DOI: 10.1007/s00228-016-2191-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Accepted: 12/28/2016] [Indexed: 11/30/2022]
Abstract
PURPOSE Nasal naloxone is wanted for bystander administration in opioid overdose and as a needle-free alternative for emergency medical personnel. Epidemiologic studies have indicated a therapeutic effect of bystander administration of low-concentration/high-volume formulations. The objective for this study was to describe the nasal pharmacokinetics of a new high-concentration/low-volume nasal formulation of naloxone. METHODS This was an open, randomized triple crossover trial in healthy, human volunteers (n = 12) where two doses of nasal naloxone (0.8 and 1.6 mg) and one intravenous dose (1.0 mg) were compared. Fifteen serum samples were collected before and until 6 h after naloxone administration. Quantification of naloxone was performed by a validated liquid chromatography-tandem mass spectrometry method. RESULTS Bioavailability was 0.54 (0.45-0.63) for the 0.8 mg and 0.52 (0.37-0.67) for the 1.6 mg nasal naloxone formulation. Maximum concentration levels (C max) were 1.45 ng/ml (1.07-1.84) for 0.8 mg and 2.57 ng/ml (1.49-3.66) for the 1.6 mg. Time to maximum concentrations (T max) were reached at 17.9 min (11.4-24.5) and 18.6 min (14.4-22.9) for the 0.8 mg and the 1.6 mg doses, respectively. CONCLUSION This nasal naloxone formulation had a rapid, systemic uptake and higher bioavailability than naloxone formulations not designed for IN use. This indicates that an optimized high-concentration/low-volume nasal spray formulation may deliver a therapeutic dose. The 1.6 mg nasal dose provided serum concentrations that surpassed those of 1.0 mg IV after 15-20 min and stayed above for the rest of the study period.
Collapse
Affiliation(s)
- Ida Tylleskar
- Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
| | - Arne Kristian Skulberg
- Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.,Division of Emergencies and Critical Care, Department of Anaesthesiology, Oslo University Hospital, Oslo, Norway
| | - Turid Nilsen
- Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
| | - Sissel Skarra
- Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
| | - Phatsawee Jansook
- Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
| | - Ola Dale
- Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. .,Department of Research and Development, St. Olav's University Hospital, Trondheim, Norway.
| |
Collapse
|
39
|
Xiao M, Huang Z, Cai J, Jia J, Zhang Y, Dong W, Wang Z. Comparison of different sample preparation methods for platinum determination in cultured cells by graphite furnace atomic absorption spectrometry. PeerJ 2017; 5:e2873. [PMID: 28123908 PMCID: PMC5248575 DOI: 10.7717/peerj.2873] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2016] [Accepted: 12/06/2016] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND Platinum-based agents are widely used in chemotherapy against solid tumors and insufficient intracellular drug accumulation is one of the leading causes of platinum resistance which is associated with poor survival of tumor patients. Thus, the detection of intracellular platinum is pivotal for studies aiming to overcome platinum resistance. In the present study, we aimed to establish a reliable graphite furnace atomic absorption spectrometry (GFAAS)-based assay to quantify the intracellular platinum content for cultured cells. METHODS Several most commonly applied cell preparation methods, including 0.2% HNO3, 0.2% Triton X-100, concentrated nitric acid, RIPA combined with concentrated nitric acid and hydroxide, followed by GFAAS for platinum detection were compared in ovarian, cervical and liver cancer cell lines to obtain the optimal one, and parameters regarding linearity, accuracy, precision and sensitivity were evaluated. Influence of other metals on platinum detection and the storage conditions of samples were also determined. RESULTS The treatment of cells with 0.2% HNO3 was superior to other approaches with fewer platinum loss and better repeatability. The recovery rate and precision of this method were 97.3%-103.0% and 1.4%-3.8%, respectively. The average recoveries in the presence of other metals were 95.1%-103.1%. The detection limit was 13.23 ug/L. The recovery rate of platinum remained acceptable even in cell samples stored in -20 °C or -80 °C for two months. DISCUSSION After comparison, we found that 0.2% HNO3 was optimal for intracellular platinum quantification based on GFAAS, which presented values compatible with that of inductively-coupled plasma mass-spectrometry (ICP-MS), and this is partially attributed to the simplicity of this method. Moreover, the assay was proved to be accurate, sensitive, cost-effective and suitable for the research of platinum-based antitumor therapy.
Collapse
Affiliation(s)
- Man Xiao
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zaiju Huang
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jing Cai
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Jinghui Jia
- Department of Obstetrics and Gynecology, Air Force General Hospital, PLA, Beijing, China
| | - Yuzeng Zhang
- Department of Occupational and Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Weihong Dong
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zehua Wang
- Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Collapse
|
40
|
Beg S, Jain A, Kaur R, Panda SS, Katare OP, Singh B. QbD-driven development and validation of an efficient bioanalytical UPLC method for estimation of olmesartan medoxomil. J LIQ CHROMATOGR R T 2016. [DOI: 10.1080/10826076.2016.1206023] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Sarwar Beg
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India
| | - Atul Jain
- UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India
| | - Ranjot Kaur
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India
| | - Sagar Suman Panda
- Department of Pharmaceutical Analysis and Quality Assurance, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
| | - O. P. Katare
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India
| | - Bhupinder Singh
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies, Panjab University, Chandigarh, India
- UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles and Nanocomposites (Biomedical Sciences), Panjab University, Chandigarh, India
| |
Collapse
|
41
|
Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J. The CGRP-Antagonist, BIBN4096BS Does not Affect Cerebral or Systemic Haemodynamics in Healthy Volunteers. Cephalalgia 2016; 25:139-47. [PMID: 15658951 DOI: 10.1111/j.1468-2982.2004.00830.x] [Citation(s) in RCA: 133] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BIBN4096BS is a CGRP-antagonist effective in the treatment of migraine. Blocking the receptor of a strong vasodilator involves a theoretical risk of causing cerebral vasoconstriction, a probability not previously investigated with BIBN4096BS. Seven healthy volunteers completed this double-blinded placebo-controlled crossover study. The volunteers received randomly 10 min infusions of either placebo, 2.5 mg or 10 mg of BIBN4096BS on 3 separate days. Transcranial Doppler was used to measure the middle cerebral artery blood flow velocity (VMCA); global and regional cerebral blood flow (rCBFMCA) was measured by 133-Xenon inhalation SPECT. The diameter of the temporal and radial artery was measured by highresolution ultrasound. Systemic haemodynamics and partial pressure of CO2 (PetCO2), and adverse events were monitored regularly. BIBN4096BS had no influence on global or regional cerebral blood flow, or on the blood flow velocity in the middle cerebral artery. There was no effect on systemic haemodynamics and adverse events were minor. We conclude that there is no effect of CGRP-receptor blockade on the cerebral or systemic circulation in humans. Circulating CGRP is therefore not likely to exert a vasodilatory activity in the resting state and the use of BIBN4096BS for acute migraine seems to be without risk of cerebral vasoactivity. These data suggest that BIBN4096BS is the first specific antimigraine drug without vasoactive effect.
Collapse
Affiliation(s)
- K A Petersen
- Danish Headache Center, University of Copenhagen, Department of Neurology, Glostrup University Hospital, DK-2600 Glostrup, Denmark.
| | | | | | | | | | | | | |
Collapse
|
42
|
Jang B, Kwon H, Katila P, Lee SJ, Lee H. Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. Adv Drug Deliv Rev 2016; 98:113-33. [PMID: 26654747 DOI: 10.1016/j.addr.2015.10.023] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2015] [Revised: 10/22/2015] [Accepted: 10/26/2015] [Indexed: 12/14/2022]
Abstract
Cancer causes >8.2 million deaths annually worldwide; thus, various cancer treatments have been investigated over the past decades. Among them, combination drug therapy has become extremely popular, and treatment with more than one drug is often necessary to achieve appropriate anticancer efficacy. With the development of nanoformulations and nanoparticulate-based drug delivery, researchers have explored the feasibility of dual delivery of biological therapeutics to overcome the current drawbacks of cancer therapy. Compared with the conventional single drug therapy, dual delivery of therapeutics has provided various synergistic effects in addition to offering multimodality to cancer treatment. In this review, we highlight and summarize three aspects of dual-delivery systems for cancer therapy. These include (1) overcoming drug resistance by the dual delivery of chemical drugs with biological therapeutics for synergistic therapy, (2) targeted and controlled drug release by the dual delivery of drugs with stimuli-responsive nanomaterials, and (3) multimodal theranostics by the dual delivery of drugs and molecular imaging probes. Furthermore, recent developments, perspectives, and new challenges regarding dual-delivery systems for cancer therapy are discussed.
Collapse
|
43
|
Davis TME, Moore BR, Salman S, Page-Sharp M, Batty KT, Manning L. Use of quantitative pharmacology tools to improve malaria treatments. Expert Rev Clin Pharmacol 2015; 9:303-16. [DOI: 10.1586/17512433.2016.1129273] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
44
|
Siegmund W, Modess C, Scheuch E, Methling K, Keiser M, Nassif A, Rosskopf D, Bednarski PJ, Borlak J, Terhaag B. Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. Br J Clin Pharmacol 2015; 79:501-13. [PMID: 25264565 DOI: 10.1111/bcp.12522] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Accepted: 09/20/2014] [Indexed: 12/19/2022] Open
Abstract
AIMS The rare association of flupirtine with liver injury is most likely caused by reactive quinone diimines and their oxidative formation may be influenced by the activities of N-acetyltransferases (NAT) that conjugate the less toxic metabolite D13223, and by glucuronosyltransferases (UGT) and glutathione S-transferases (GST) that generate stable terminal glucuronides and mercapturic acid derivatives, respectively. The influence of genetic polymorphisms of NAT2, UGT1A1 and GSTP1 on generation of the terminal mercapturic acid derivatives and analgesic effects was evaluated to identify potential genetic risk factors for hepatotoxicity of flupirtine. METHODS Metabolic disposition of flupirtine was measured after intravenous administration (100 mg), after swallowing an immediate-release (IR) tablet (100 mg) and after repeated administration of modified release (MR) tablets (400 mg once daily 8 days) in 36 selected healthy subjects. Analgesic effects were measured using pain models (delayed onset of muscle soreness, electric pain). RESULTS Flupirtine IR was rapidly but incompletely absorbed (∼ 72%). Repeated administration of flupirtine MR showed lower bioavailability (∼ 60%). Approximately 12% of bioavailable flupirtine IR and 8% of bioavailable flupiritine MR was eliminated as mercapturic acid derivatives into the urine independent of the UGT1A1, NAT2 and GSTP1 genotype. Carriers of variant GSTP1 alleles showed lower bioavailability but increased intestinal secretion of flupirtine and increased efficiency in experimental pain. Flupirtine was not a substrate for ABCB1 and ABCC2. CONCLUSIONS Formation of mercapturic acid derivatives is a major elimination route for flupirtine in man. However, the theoretically toxic pathway is not influenced by the frequent polymorphisms of UGT1A1, NAT2 and GSTP1.
Collapse
Affiliation(s)
- Werner Siegmund
- Department of Clinical Pharmacology, University Medicine Greifswald, Greifswald, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Kolbow J, Modess C, Wegner D, Oswald S, Maritz MA, Rey H, Weitschies W, Siegmund W. Extended-release but not immediate-release and subcutaneous methylnaltrexone antagonizes the loperamide-induced delay of whole-gut transit time in healthy subjects. J Clin Pharmacol 2015; 56:239-45. [DOI: 10.1002/jcph.624] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 08/24/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Julia Kolbow
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | - Christiane Modess
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | - Danilo Wegner
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | - Stefan Oswald
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| | | | - Hélène Rey
- Develco Pharma Schweiz AG; Pratteln Switzerland
| | - Werner Weitschies
- Department of Pharmaceutical Technology and Biopharmacy, Center of Drug Absorption and Transport; University of Greifswald; Greifswald Germany
| | - Werner Siegmund
- Department of Clinical Pharmacology, Center of Drug Absorption and Transport; University Medicine; Greifswald Germany
| |
Collapse
|
46
|
Beg S, Chaudhary V, Sharma G, Garg B, Panda SS, Singh B. QbD-oriented development and validation of a bioanalytical method for nevirapine with enhanced liquid-liquid extraction and chromatographic separation. Biomed Chromatogr 2015; 30:818-28. [DOI: 10.1002/bmc.3613] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 08/14/2015] [Accepted: 09/07/2015] [Indexed: 11/07/2022]
Affiliation(s)
- Sarwar Beg
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies; Panjab University; Chandigarh 160 014 India
| | - Vandna Chaudhary
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies; Panjab University; Chandigarh 160 014 India
| | - Gajanand Sharma
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies; Panjab University; Chandigarh 160 014 India
- Formulation Research and Tech Transfer; IPCA Laboratories Limited; Kadhivali (W) Mumbai 400 067 India
| | - Babita Garg
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies; Panjab University; Chandigarh 160 014 India
| | - Sagar Suman Panda
- Department of Pharmaceutical Analysis and Quality Assurance; Roland Institute of Pharmaceutical Sciences; Berhampur Odisha 760 010 India
| | - Bhupinder Singh
- University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Studies; Panjab University; Chandigarh 160 014 India
| |
Collapse
|
47
|
Kurita GP, Lundström S, Sjøgren P, Ekholm O, Christrup L, Davies A, Kaasa S, Klepstad P, Dale O. Renal function and symptoms/adverse effects in opioid-treated patients with cancer. Acta Anaesthesiol Scand 2015; 59:1049-59. [PMID: 25943005 DOI: 10.1111/aas.12521] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Revised: 06/19/2014] [Accepted: 03/02/2015] [Indexed: 11/30/2022]
Abstract
BACKGROUND Renal impairment and the risk of toxicity caused by accumulation of opioids and/or active metabolites is an under-investigated issue. This study aimed at analysing if symptoms/adverse effects in opioid-treated patients with cancer were associated with renal function. METHODS Cross-sectional multicentre study (European Pharmacogenetic Opioid Study, 2005-2008), in which 1147 adult patients treated exclusively with only one of the most frequently reported opioids (morphine/oxycodone/fentanyl) for at least 3 days were analysed. Fatigue, nausea/vomiting, pain, loss of appetite, constipation and cognitive dysfunction were assessed (EORTC QLQ-C30). Glomerular filtration rate (GFR) was estimated using Cockcroft-Gault (CG), Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI Creatinine) equations. RESULTS Mild to severe low GFR was observed among 40-54% of patients. CG equation showed that patients with mild and moderate/severe low GFR on morphine treatment had higher odds of having severe constipation (P < 0.01) than patients with normal GFR. In addition, patients with moderate/severe low GFR on morphine treatment were more likely to have loss of appetite (P = 0.04). No other significant associations were found. CONCLUSION Only severe constipation and loss of appetite were associated with low GFR in patients treated with morphine. Oxycodone and fentanyl, in relation to the symptoms studied, seem to be safe as used and titrated in routine cancer pain care.
Collapse
Affiliation(s)
- G. P. Kurita
- Department of Oncology; Rigshospitalet Copenhagen University Hospital; Copenhagen Denmark
- Multidisciplinary Pain Centre; Department of Neuroanaesthesiology; Rigshospitalet Copenhagen University Hospital; Copenhagen Denmark
| | - S. Lundström
- Stockholms Sjukhem Foundation and Department of Oncology Pathology; Karolinska Institute; Stockholm Sweden
| | - P. Sjøgren
- Department of Oncology; Rigshospitalet Copenhagen University Hospital; Copenhagen Denmark
- Department of Clinical Medicine; Faculty of Health and Medical Sciences; University of Copenhagen; Copenhagen Denmark
| | - O. Ekholm
- National Institute of Public Health; University of Southern Denmark; Copenhagen Denmark
| | - L. Christrup
- Department of Drug Design and Pharmacology; Faculty of Health and Medical Sciences; University of Copenhagen; Copenhagen Denmark
| | - A. Davies
- Royal Surrey County Hospital; Guildford UK
| | - S. Kaasa
- Department of Oncology; Trondheim University Hospital; St. Olav Hospital; Trondheim Norway
- European Palliative Care Research Centre; DMF; Norwegian University of Science and Technology; Trondheim Norway
| | - P. Klepstad
- Department of Intensive Care Medicine; St Olavs University Hospital; Trondheim Norway
- Department of Circulation and Medical Imaging; Norwegian University of Science and Technology; Trondheim Norway
| | - O. Dale
- Department of Circulation and Medical Imaging; Norwegian University of Science and Technology; Trondheim Norway
| |
Collapse
|
48
|
Kaity S, Ghosh A. Comparative bio-safety and in vivo evaluation of native or modified locust bean gum-PVA IPN microspheres. Int J Biol Macromol 2015; 72:883-93. [PMID: 25307127 DOI: 10.1016/j.ijbiomac.2014.09.036] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2014] [Revised: 09/16/2014] [Accepted: 09/21/2014] [Indexed: 11/28/2022]
Abstract
Strategically developed natural polymer-based controlled release multiparticulate drug delivery systems have gained special interest for “spatial placement” and “temporal delivery” of drug molecules. In our earlier study, locust bean gum-poly(vinyl alcohol) interpenetrating polymer network (LBG-PVA IPN), carboxymethylated locust bean gum-poly(vinyl alcohol) interpenetrating polymer network (CMLBG-PVA IPN) and acrylamide grafted locust bean gum-poly(vinyl alcohol) interpenetrating polymer network (Am-g-LBG-PVA IPN) were prepared and characterized. The present study deals with accelerating stability testing, comparative bio-safety and single dose in vivo pharmacokinetic study of all three IPN microspheres for controlled oral delivery of buflomedil hydrochloride (BH). From the stability study, it was observed that the particles were stable throughout the study period. From toxicity and biodegradability study it was proved that the microspheres were safe for internal use and complied with bio-safety criterion. From the in vivo pharmacokinetic study in rabbits, it was observed that the CMLBG-PVA IPN microspheres possessed almost similar Tmax value with BH oral suspension. However, in comparison between the LBG-PVA and Am-g-LBG-PVA IPN microspheres, the later showed well controlled release property than the first in biological condition. Thus, this type of delivery system might be useful to achieve the lofty goals of the controlled release drug delivery.
Collapse
|
49
|
Chanteux H, Staelens L, Mancel V, Gerin B, Boucaut D, Prakash C, Nicolas JM. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist. Drug Metab Dispos 2015; 43:1381-91. [PMID: 26153275 DOI: 10.1124/dmd.115.064436] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Accepted: 07/07/2015] [Indexed: 12/17/2022] Open
Abstract
CT7758, a carboxylate containing α4β1/α4/β7 integrin antagonist, was characterized for its pharmacokinetic profile in various in vitro and in vivo assays in support of clinical development. The oral bioavailability of CT7758 was 4% in mice, 2% in rats, 7-55% in dogs, and 0.2% in cynomolgus monkeys. The low bioavailability in rodents and monkey results from low intestinal absorption as evidenced by a low fraction absorbed in the rat portal vein model (3%), low-to-medium permeability in Caco-2 cells (≤1.3 × 10(-6) cm/s) with evidences of polarized efflux, and high polar surface area (104 Å). In rodents and cynomolgus monkeys, the total plasma clearance was moderate to high (≥50% hepatic blood flow QH) and associated with a short elimination half-life (≤1 hour). This contrast with the dog data which showed a much lower clearance (6% QH) and a longer t1/2 (2.4 hours). The volume of distribution (Vz) also varied significantly across species with value of 5.5, 2.8, 0.24, and 0.93 l/kg in mouse, rat, dog, and cynomolgus monkey, respectively. In vitro assays demonstrated that active hepatic uptake accounted for most of the in vivo clearance and was the source of the large species variability. In vitro uptake assays predicted a total plasma clearance in humans in the low range (33% QH), a finding subsequently confirmed in the clinic. Assays in OAPT1B1-transfected cells demonstrated active uptake transport through this transporter. The prospect of limited absorption in human prompted the synthesis an ethyl ester prodrug, CDP323, which demonstrated higher in vitro permeability, increased oral bioavailability, as well as efficient in vivo release of its active moiety CT7758.
Collapse
Affiliation(s)
- Hugues Chanteux
- UCB Pharma SA, Investigative ADME (H.C., V.M., B.G.), Bioanalytical Sciences (L.S.), Laboratory Animal Services (D.B.), Braine l'Alleud, Belgium; Strategic DMPK Support, Braine l'Alleud, Belgium (J.M.N.); and Biogen Idec, Drug Metabolism and Pharmacokinetics, Biogen Idec, Cambridge, Massachusetts (C.P.)
| | - Ludovicus Staelens
- UCB Pharma SA, Investigative ADME (H.C., V.M., B.G.), Bioanalytical Sciences (L.S.), Laboratory Animal Services (D.B.), Braine l'Alleud, Belgium; Strategic DMPK Support, Braine l'Alleud, Belgium (J.M.N.); and Biogen Idec, Drug Metabolism and Pharmacokinetics, Biogen Idec, Cambridge, Massachusetts (C.P.)
| | - Valérie Mancel
- UCB Pharma SA, Investigative ADME (H.C., V.M., B.G.), Bioanalytical Sciences (L.S.), Laboratory Animal Services (D.B.), Braine l'Alleud, Belgium; Strategic DMPK Support, Braine l'Alleud, Belgium (J.M.N.); and Biogen Idec, Drug Metabolism and Pharmacokinetics, Biogen Idec, Cambridge, Massachusetts (C.P.)
| | - Brigitte Gerin
- UCB Pharma SA, Investigative ADME (H.C., V.M., B.G.), Bioanalytical Sciences (L.S.), Laboratory Animal Services (D.B.), Braine l'Alleud, Belgium; Strategic DMPK Support, Braine l'Alleud, Belgium (J.M.N.); and Biogen Idec, Drug Metabolism and Pharmacokinetics, Biogen Idec, Cambridge, Massachusetts (C.P.)
| | - David Boucaut
- UCB Pharma SA, Investigative ADME (H.C., V.M., B.G.), Bioanalytical Sciences (L.S.), Laboratory Animal Services (D.B.), Braine l'Alleud, Belgium; Strategic DMPK Support, Braine l'Alleud, Belgium (J.M.N.); and Biogen Idec, Drug Metabolism and Pharmacokinetics, Biogen Idec, Cambridge, Massachusetts (C.P.)
| | - Chandra Prakash
- UCB Pharma SA, Investigative ADME (H.C., V.M., B.G.), Bioanalytical Sciences (L.S.), Laboratory Animal Services (D.B.), Braine l'Alleud, Belgium; Strategic DMPK Support, Braine l'Alleud, Belgium (J.M.N.); and Biogen Idec, Drug Metabolism and Pharmacokinetics, Biogen Idec, Cambridge, Massachusetts (C.P.)
| | - Jean-Marie Nicolas
- UCB Pharma SA, Investigative ADME (H.C., V.M., B.G.), Bioanalytical Sciences (L.S.), Laboratory Animal Services (D.B.), Braine l'Alleud, Belgium; Strategic DMPK Support, Braine l'Alleud, Belgium (J.M.N.); and Biogen Idec, Drug Metabolism and Pharmacokinetics, Biogen Idec, Cambridge, Massachusetts (C.P.)
| |
Collapse
|
50
|
Wooding KM, Hankin JA, Johnson CA, Chosich JD, Baek SW, Bradford AP, Murphy RC, Santoro N. Measurement of estradiol, estrone, and testosterone in postmenopausal human serum by isotope dilution liquid chromatography tandem mass spectrometry without derivatization. Steroids 2015; 96:89-94. [PMID: 25617740 PMCID: PMC4366052 DOI: 10.1016/j.steroids.2015.01.007] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Revised: 12/10/2014] [Accepted: 01/11/2015] [Indexed: 10/24/2022]
Abstract
BACKGROUND A high-throughput, sensitive, specific, mass spectrometry-based method for quantitating estrone (E1), estradiol (E2), and testosterone (T) in postmenopausal human serum has been developed for clinical research. The method consumes 100μl human serum for each measurement (triplicates consume 300μl) and does not require derivatization. We adapted a commercially available 96-well plate for sample preparation, extraction, and introduction into the mass spectrometer on a single platform. METHODS Steroid extraction from serum samples and mass spectrometer operational parameters were optimized for analysis of estradiol and subsequently applied to other analytes. In addition to determining the limit of detection (LOD) and limit of quantitation (LOQ) from standard curves, a serum LOQ (sLOQ) was determined by addition of known steroid quantities to serum samples. Mass spectrometric method quantitative data were compared to results using a state-of-the-art ELISA (enzyme-linked immunosorbent assay) using stored serum samples from menopausal women. RESULTS The LOD, LOQ, sLOQ was (0.1pg, 0.3pg, 1pg/ml) for estrone, (0.3pg, 1pg, 3pg/ml) for estradiol, and (0.3pg, 1pg, 30pg/ml) for testosterone, respectively. Mass spectrometry accurately determined concentrations of E2 that could not be quantified by immunochemical methods. E1 concentrations measured by mass spectrometry were in all cases significantly lower than the ELISA measurements, suggesting immunoreactive contaminants in serum may interfere with ELISA. The testosterone measurements broadly agreed with each other in that both techniques could differentiate between low, medium and high serum levels. CONCLUSIONS We have developed and validated a scalable, sensitive assay for trace quantitation of E1, E2 and T in human serum samples in a single assay using sample preparation method and stable isotope dilution mass spectrometry.
Collapse
Affiliation(s)
- Kerry M Wooding
- Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, United States; Department of Pharmacology, University of Colorado Denver, Aurora, CO, United States
| | - Joseph A Hankin
- Department of Pharmacology, University of Colorado Denver, Aurora, CO, United States
| | - Chris A Johnson
- Department of Pharmacology, University of Colorado Denver, Aurora, CO, United States
| | - Justin D Chosich
- Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, United States
| | - Sung W Baek
- Department of Sample Preparation Products, Biotage, Charlotte, NC, United States
| | - Andrew P Bradford
- Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, United States
| | - Robert C Murphy
- Department of Pharmacology, University of Colorado Denver, Aurora, CO, United States
| | - Nanette Santoro
- Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, United States.
| |
Collapse
|